UCLA Develops More Efficient And Affordable Therapeutics

UCLA

Entropic Biosciences, Inc. is a UCLA spin-out biotechnology company that has developed innovative, biology-inspired technology to make the costly development of therapeutics more efficient and affordable. Entropic has been recognized by the National Inventors Hall of Fame and has received USPTO patent acceleration for its groundbreaking platform technology, which assembles cells into 3D organoids and tissues in less than 24 hours — a feat unmatched in the biotech industry. This first-in-class, proprietary technology addresses the current limitation in various hydrogel-based materials for the creation of spheroids/organoid for 3D cell culture and precision medicine applications.



The scientists behind Entropic Biosciences invented the platform as researchers at UCLA, where they licensed it through UCLA Technology Development Group, the university's tech transfer office, to further develop and commercialize their work through their startup. Dr. Amir Nasajpour developed this technology during his PhD in materials chemistry at UCLA. He serves as the CEO/President of Entropic Biosciences. Co-Founder UCLA Professor Paul S. Weiss holds a UC Presidential Chair, is a Distinguished Professor of Chemistry and Biochemistry, Bioengineering, and Materials Science and Engineering. He founded and leads the Challenge Initiative at UCLA, which aims to develop novel solutions and intellectual property for significant unsolved problems.

This story was originally published in 2025.

Share your story at autm.net/betterworldproject #betterworldproject